74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vetoquinol SA
Open
SectorHealthcare
73.6 -5.28
Overview
Share price change
24h
Min
65.8
Max
79.1
Income | 24M |
|---|---|
Sales | 264M |
P/E Sector Avg | 18.998 57.333 |
Dividend yield | 1.11 |
Profit margin | 9.003 |
EBITDA | 45M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +51.9% upside |
Dividend yield Sector Avg | 1.11% 2.63% |
|---|
Market Cap | 897M |
|---|---|
Previous open | 78.88 |
Previous close | 73.6 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Vetoquinol SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vetoquinol SA Forecast
Price Target
By TipRanks
51.9% upside
12 Months Forecast
Average 120 EUR 51.9%
High 120 EUR
Low 120 EUR
Based on 1 Wall Street analysts offering 12 month price targets forVetoquinol SA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
